Lisata Therapeutics, Inc.

DB:8NE Stock Report

Market Cap: €23.0m

Lisata Therapeutics Valuation

Is 8NE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8NE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 8NE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 8NE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8NE?

Key metric: As 8NE is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 8NE. This is calculated by dividing 8NE's market cap by their current book value.
What is 8NE's PB Ratio?
PB Ratio0.7x
BookUS$33.69m
Market CapUS$23.96m

Price to Book Ratio vs Peers

How does 8NE's PB Ratio compare to its peers?

The above table shows the PB ratio for 8NE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average11.8x
MDG1 Medigene
1.2x-4.1%€22.6m
VSC 4SC
44xn/a€48.2m
2INV 2invest
1xn/a€63.8m
CNW co.don
1xn/a€6.5m
8NE Lisata Therapeutics
0.7x-3.2%€24.0m

Price-To-Book vs Peers: 8NE is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (15.4x).

Price to Book Ratio vs Industry

How does 8NE's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
8NE 0.7xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 8NE is good value based on its Price-To-Book Ratio (0.7x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 8NE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8NE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 8NE's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8NE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.64
€12.89
+388.3%
7.1%€13.81€11.97n/a2
Nov ’25€2.52
€12.89
+411.6%
7.1%€13.81€11.97n/a2
Oct ’25€2.62
€13.19
+403.3%
3.4%€13.64€12.73n/a2
Sep ’25€2.64
€13.19
+399.5%
3.4%€13.64€12.73n/a2
Aug ’25€2.90
€13.30
+358.7%
3.4%€13.76€12.84n/a2
Jul ’25€3.26
€13.50
+314.1%
3.4%€13.97€13.03n/a2
Jun ’25€2.80
€13.36
+377.1%
3.4%€13.82€12.90n/a2
May ’25€2.50
€13.52
+440.7%
3.4%€13.98€13.05n/a2
Apr ’25€2.84
€13.38
+371.1%
3.4%€13.84€12.92n/a2
Mar ’25€2.64
€13.38
+406.8%
3.4%€13.84€12.92n/a2
Feb ’25€2.22
€14.24
+541.6%
3.2%€14.70€13.79n/a2
Jan ’25€2.48
€14.46
+482.9%
3.2%€14.92€13.99n/a2
Dec ’24€1.93
€14.46
+649.0%
3.2%€14.92€13.99n/a2
Nov ’24€1.86
€14.66
+687.9%
3.2%€15.13€14.18€2.522
Oct ’24€1.90
€14.22
+648.2%
3.2%€14.67€13.76€2.622
Sep ’24€1.94
€14.22
+632.7%
3.2%€14.67€13.76€2.642
Aug ’24€2.80
€14.46
+416.5%
3.2%€14.93€14.00€2.902
Jul ’24€3.24
€14.46
+346.4%
3.2%€14.93€14.00€3.262
Jun ’24€3.80
€14.46
+280.6%
3.2%€14.93€14.00€2.802
May ’24€2.92
€14.29
+389.4%
3.2%€14.75€13.83€2.502
Apr ’24€2.80
€14.29
+410.3%
3.2%€14.75€13.83€2.842
Mar ’24€2.70
€14.36
+432.0%
3.2%€14.83€13.90€2.642
Feb ’24€3.16
€14.36
+354.6%
3.2%€14.83€13.90€2.222
Jan ’24€2.16
€28.96
+1,240.8%
50.0%€43.44€14.48€2.482
Dec ’23€3.24
€28.96
+793.9%
50.0%€43.44€14.48€1.932
Nov ’23€4.22
€30.71
+627.7%
50.0%€46.06€15.35€1.862

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

7D

-1.6%

1Y

-38.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

7D

-1.8%

1Y

0.2%